- Glucagon-like peptide-1 receptor agonists in peri-operative care
European Journal of Anaesthesiology · 2024
- Cardiovascular and renal effects of the combination therapy of a GLP-1 receptor agonist and an SGLT2 inhibitor in observational real-life studies
Diabetes & Metabolism · 2024
- Impact of semaglutide on weight and functional outcomes among obese heart failure patients: a propensity scores matching analysis
BMC Cardiovascular Disorders · 2024
- GLP-1 receptor agonists as promising anti-inflammatory agents in heart failure with preserved ejection fraction
Heart Failure Reviews · 2024
- Anti-atherosclerotic effect of incretin receptor agonists
Frontiers in Endocrinology · 2024
- The Impact of Glucagon-Like Peptide-1 Receptor Agonists on Kidney Outcomes
Clinical Journal of the American Society of Nephrology · 2024
- Combining GLP-1 receptor agonists and SGLT-2 inhibitors for cardiovascular disease prevention in type 2 diabetes: A systematic review with multiple network meta-regressions
World Journal of Diabetes · 2024
- Semaglutide and blood pressure: an individual patient data meta-analysis
European Heart Journal · 2024
- Evaluating Cardiovascular Benefits of Glucagon-Like Peptide-1 Receptor Agonists (GLP-1 RAs) in Type 2 Diabetes Mellitus: A Systematic Review
Cureus · 2024
- Glucagon‐like peptide‐1 receptor agonist semaglutide reduces atrial fibrillation incidence: A systematic review and meta‐analysis
European Journal of Clinical Investigation · 2024
- New insights into the effects of glucagon-like peptide-1 on heart rate and sinoatrial node function
Cardiovascular Research · 2024
- Gastric ultrasound and mitigating risk of glucagon‐like peptide‐1 receptor agonists
Anaesthesia · 2024
- Glucagon-Like Peptide-1 Receptor Agonists and Sodium Glucose Cotransporter-2 Inhibitors and Cardiorespiratory Fitness Interaction
Military Medicine · 2024
- Glucagon-like peptide-1 receptor agonists and stroke: A systematic review and meta-analysis of cardiovascular outcome trials
International Journal of Stroke · 2024
- The effect of glucagon‐like peptide‐1 receptor agonists on cardiac function and structure in patients with or without type 2 diabetes mellitus: An updated systematic review and meta‐analysis
Diabetes Obesity and Metabolism · 2024
- Potential Mediators for Treatment Effects of Novel Diabetes Medications on Cardiovascular and Renal Outcomes: A Meta‐Regression Analysis
Journal of the American Heart Association · 2024
- Perioperative management of patients on glucagon-like peptide-1 receptor agonists
Current Opinion in Anaesthesiology · 2024
- Paradoxical real-life underuse of GLP-1 receptor agonists in type 2 diabetes patients with atherosclerotic cardiovascular disease
Diabetes Epidemiology and Management · 2024
- Absolute treatment effects of novel antidiabetic drugs on a composite renal outcome: meta-analysis of digitalized individual patient data
Journal of Nephrology · 2024
- Effects of glucagon-like peptide-1 receptor agonists on liver-related and cardiovascular mortality in patients with type 2 diabetes
BMC Medicine · 2024
- Safety, pharmacokinetics and pharmacodynamics of <scp>HRS</scp> ‐7535, a novel oral small molecule glucagon‐like peptide‐1 receptor agonist, in healthy participants: A phase 1, randomized, double‐blind, placebo‐controlled, single‐ and multiple‐ascending dose, and food effect trial
Diabetes Obesity and Metabolism · 2023
- Obesity, heart failure with preserved ejection fraction, and the role of glucagon‐like peptide‐1 receptor agonists
ESC Heart Failure · 2023
- ASA Consensus-based Guidance on Preoperative Management of Patients on Glucagon-like Peptide-1 Receptor Agonists
Anesthesiology · 2023
- Once-weekly glucagon-like peptide-1 receptor agonists vs dipeptidyl peptidase-4 inhibitors: cardiovascular effects in people with diabetes and cardiovascular disease
Cardiovascular Diabetology · 2023
- Renoprotective effects of combination treatment with sodium-glucose cotransporter inhibitors and GLP-1 receptor agonists in patients with type 2 diabetes mellitus according to preceding medication
Diabetes and Vascular Disease Research · 2023
- Impact of a dual glucose‐dependent insulinotropic peptide/ glucagon‐like peptide ‐1 receptor agonist tirzepatide on heart rate among patients with type 2 diabetes: A systematic review and pairwise and network meta‐analysis
Diabetes Obesity and Metabolism · 2023
- Racial, ethnic and regional differences in the effect of sodium–glucose co-transporter 2 inhibitors and glucagon-like peptide 1 receptor agonists on cardiovascular and renal outcomes: a systematic review and meta-analysis of cardiovascular outcome trials
Journal of the Royal Society of Medicine · 2023
- Letter to Editor From Banerjee et al: “Glucagon-Like Peptide-1 Receptor Agonists Across the Spectrum of Heart Failure”
The Journal of Clinical Endocrinology & Metabolism · 2023
- Effects of once‐weekly glucagon‐like peptide‐1 receptor agonists on type 2 diabetes mellitus complicated with coronary artery disease: Potential role of the renin‐angiotensin system
Diabetes Obesity and Metabolism · 2023
- Glucagon-Like Peptide-1 Receptor Agonists Across the Spectrum of Heart Failure
The Journal of Clinical Endocrinology & Metabolism · 2023
- The Effect of GLP-1 on the Incidence of Cardiovascular Events Compared to Bariatric Surgery: Systematic Review
Acta Scientific Medical Sciences · 2023
- GLP-1 Receptor Agonists and SGLT-2 Inhibitors in Patients With Versus Without Cardiovascular Disease: A Systematic Review, Meta-analysis, and Trial Sequential Analysis
Angiology · 2023
- Effects of new hypoglycemic drugs on cardiac remodeling: a systematic review and network meta-analysis
BMC Cardiovascular Disorders · 2023
- Kidney function loss and albuminuria progression with GLP-1 receptor agonists versus basal insulin in patients with type 2 diabetes: real-world evidence
Cardiovascular Diabetology · 2023
- A randomized Phase I study of the safety, tolerability, pharmacokinetics and pharmacodynamics of <scp>BI</scp> 456906, a dual glucagon receptor/glucagon‐like peptide‐1 receptor agonist, in healthy Japanese men with overweight/obesity
Diabetes Obesity and Metabolism · 2023
- Systolic blood pressure reduction with tirzepatide in patients with type 2 diabetes: insights from SURPASS clinical program
Cardiovascular Diabetology · 2023
- The cardiovascular and renal effects of glucagon-like peptide 1 receptor agonists in patients with advanced diabetic kidney disease
Cardiovascular Diabetology · 2023
- Glucagon-Like Peptide-1 Protects Against Atrial Fibrillation and Atrial Remodeling in Type 2 Diabetic Mice
JACC Basic to Translational Science · 2023
- Effects of glucagon‐like peptide‐1 receptor agonists on major coronary events in patients with type 2 diabetes
Diabetes Obesity and Metabolism · 2023
- Glucagon-Like Peptide-1 Receptor Agonist Protects Against Diabetic Cardiomyopathy by Modulating microRNA-29b-3p/SLMAP
Drug Design Development and Therapy · 2023
- Cardioprotective effects of liraglutide pretreatment on isoprenaline-induced myocardial injury in rats
Canadian Journal of Physiology and Pharmacology · 2023
- Pleiotropic effects of GLP‐1 receptor agonists on peripheral artery disease: Is there any hope?
Diabetes/Metabolism Research and Reviews · 2023
- Comparative efficacy of <scp>sodium‐glucose</scp> co‐transporter‐2 inhibitors, <scp>glucagon‐like</scp> peptide‐1 receptor agonists and non‐steroidal mineralocorticoid receptor antagonists in chronic kidney disease and type 2 diabetes: A systematic review and network <scp>meta‐analysis</scp>
Diabetes Obesity and Metabolism · 2023
- Impact of chronic GLP-1 RA and SGLT-2I therapy on in-hospital outcome of diabetic patients with acute myocardial infarction
Cardiovascular Diabetology · 2023
- Phase I studies of the safety, tolerability, pharmacokinetics and pharmacodynamics of the dual glucagon receptor/glucagon‐like peptide‐1 receptor agonist <scp>BI</scp> 456906
Diabetes Obesity and Metabolism · 2022
- Can glucagon-like peptide-1 receptor agonists cause acute kidney injury? An analytical study based on post-marketing approval pharmacovigilance data
Frontiers in Endocrinology · 2022
- A phase 1 study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of danuglipron ( PF ‐06882961), an oral small‐molecule glucagon‐like peptide‐1 receptor agonist, in Japanese adults with type 2 diabetes mellitus
Diabetes Obesity and Metabolism · 2022
- Network meta-analysis on the effects of finerenone versus SGLT2 inhibitors and GLP-1 receptor agonists on cardiovascular and renal outcomes in patients with type 2 diabetes mellitus and chronic kidney disease
Cardiovascular Diabetology · 2022
- Depot-specific adipose tissue modulation by SGLT2 inhibitors and GLP1 agonists mediates their cardioprotective effects in metabolic disease
Clinical Science · 2022
- Effects of GLP ‐1 receptor agonists on cardiovascular outcomes in patients with type 2 diabetes and chronic kidney disease: A systematic review and meta‐analysis
Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · 2022